P-196 CA 19-9 and CEA as markers of survival in rectal cancer

Abstract

Background: Treatment options for patients (pts) with metastatic colorectal cancer (mCRC) after progression to standard therapy are limited. Trifluridine/tipiracil (TAS-102) is an orally administered cytotoxic agent approved for the treatment of patients with refractory mCRC. Patients treated with TAS-102 derived a significant benefit in OS compared with placebo as demonstrated in two phase III trials (RESOURCE and TERRA). However, real-world data on the effectiveness of TAS-102 are sparse. Methods:The aim of this observational study was to investigate the efficacy and safety of TAS-102. We included 72 pts (47 men, 25 women) who began treatment with TAS-102 between May 1st, 2018 and Dec 31st, 2019 in the University Hospital Centre Zagreb. Eligible pts had metastatic disease and were in good general condition (ECOG 1). Forty-three started irinotecan-and 29 pts oxaliplatin-based chemotherapy (CT) with a biological agent added according to RAS status in 53 pts. TAS-102 was introduced after progression to two standard treatment lines. Outcomes were measured as PFS in the 3rd line and overall duration of therapy (DoT). To further assess the potential influence of other variables, correlation with Spearman's rank test was used.